Cholera
diseaseOn this page
Also known as cholera due to Vibrio choleraeVibrio cholerae caused disease or disorderVibrio cholerae disease or disorderVibrio cholerae infectionVibrio cholerae infectious disease
Summary
Cholera (MONDO:0015766) is a disease and 64 clinical trials. Top therapeutic interventions include vibrio cholerae, live attenuated, ciprofloxacin, and albendazole. A subtype of primary bacterial infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Prevalence: <1 / 1 000 000 (Europe) [Orphanet-validated]
- Phenotypes (HPO): 34
- Clinical trials: 64
Clinical features
Epidemiology
Prevalence records
13 prevalence record(s), Orphanet:
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Annual incidence | <1 / 1 000 000 | Europe | Validated | |
| Point prevalence | <1 / 1 000 000 | Europe | Validated | |
| Annual incidence | <1 / 1 000 000 | United Kingdom | Validated | |
| Annual incidence | <1 / 1 000 000 | Germany | Validated | |
| Annual incidence | <1 / 1 000 000 | Austria | Validated | |
| Annual incidence | <1 / 1 000 000 | Belgium | Validated | |
| Annual incidence | <1 / 1 000 000 | Czech Republic | Validated | |
| Annual incidence | <1 / 1 000 000 | Denmark | Validated | |
| Annual incidence | <1 / 1 000 000 | France | Validated | |
| Annual incidence | <1 / 1 000 000 | Norway | Validated | |
| Annual incidence | <1 / 1 000 000 | Spain | Validated | |
| Annual incidence | <1 / 1 000 000 | Sweden | Validated | |
| Point prevalence | <1 / 1 000 000 | United States | Validated |
Signs & symptoms
Clinical features (HPO)
34 HPO clinical features (Orphanet curated; top 34 by frequency):
| HPO ID | Term | Frequency |
|---|---|---|
| HP:0002014 | Diarrhea | Very frequent (80-99%) |
| HP:0001324 | Muscle weakness | Frequent (30-79%) |
| HP:0001649 | Tachycardia | Frequent (30-79%) |
| HP:0001941 | Acidosis | Frequent (30-79%) |
| HP:0001944 | Dehydration | Frequent (30-79%) |
| HP:0002013 | Vomiting | Frequent (30-79%) |
| HP:0002615 | Hypotension | Frequent (30-79%) |
| HP:0002900 | Hypokalemia | Frequent (30-79%) |
| HP:0002901 | Hypocalcemia | Frequent (30-79%) |
| HP:0002902 | Hyponatremia | Frequent (30-79%) |
| HP:0003111 | Abnormal blood ion concentration | Frequent (30-79%) |
| HP:0003394 | Muscle spasm | Frequent (30-79%) |
| HP:0011036 | Abnormality of renal excretion | Frequent (30-79%) |
| HP:0011037 | Decreased urine output | Frequent (30-79%) |
| HP:0000490 | Deeply set eye | Occasional (5-29%) |
| HP:0000737 | Irritability | Occasional (5-29%) |
| HP:0001250 | Seizure | Occasional (5-29%) |
| HP:0001254 | Lethargy | Occasional (5-29%) |
| HP:0001622 | Premature birth | Occasional (5-29%) |
| HP:0001919 | Acute kidney injury | Occasional (5-29%) |
| HP:0001943 | Hypoglycemia | Occasional (5-29%) |
| HP:0002027 | Abdominal pain | Occasional (5-29%) |
| HP:0002789 | Tachypnea | Occasional (5-29%) |
| HP:0002883 | Hyperventilation | Occasional (5-29%) |
| HP:0003128 | Lactic acidosis | Occasional (5-29%) |
| HP:0005268 | Spontaneous abortion | Occasional (5-29%) |
| HP:0007185 | Loss of consciousness | Occasional (5-29%) |
| HP:0007517 | Palmoplantar cutis laxa | Occasional (5-29%) |
| HP:0031274 | Hypovolemic shock | Occasional (5-29%) |
| HP:0032155 | Abdominal cramps | Occasional (5-29%) |
| HP:0032448 | Achlorhydria | Occasional (5-29%) |
| HP:0001297 | Stroke | Very rare (<1-4%) |
| HP:0001945 | Fever | Very rare (<1-4%) |
| HP:0011951 | Aspiration pneumonia | Very rare (<1-4%) |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | cholera |
| Mondo ID | MONDO:0015766 |
| MeSH | D002771 |
| Orphanet | 173 |
| DOID | DOID:1498 |
| ICD-10-CM | A00 |
| ICD-11 | 257068234 |
| NCIT | C157812 |
| SNOMED CT | 63650001 |
| UMLS | C0008354 |
| MedGen | 40263 |
| GARD | 0006043 |
| MedDRA | 10008631 |
| NORD | 928 |
| Is cancer (heuristic) | no |
Also known as: cholera due to Vibrio cholerae · Vibrio cholerae caused disease or disorder · Vibrio cholerae disease or disorder · Vibrio cholerae infection · Vibrio cholerae infectious disease
Disease family
This is a subtype of primary bacterial infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › primary bacterial infectious disease › cholera
Related subtypes (36): Buruli ulcer disease, sennetsu fever, salmonellosis, pinta disease, chancroid, gonorrhea, anthrax infection, leprosy, botulism, diphtheria, tetanus, bartonellosis, brucellosis, campylobacteriosis, glanders, granuloma inguinale, legionellosis, leptospirosis, listeriosis, Mycobacterium avium complex disease, ornithosis, rhinoscleroma, staphyloenterotoxemia, syphilis, ehrlichiosis, melioidosis, tuberculosis, tularemia, plague, Q fever, shigellosis, Lyme disease, relapsing fever, spirillary rat-bite fever, streptobacillary rat-bite fever, Borrelia miyamotoi disease
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 64.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 22 |
| PHASE3 | 15 |
| PHASE2 | 14 |
| PHASE4 | 7 |
| PHASE1 | 3 |
| PHASE1/PHASE2 | 2 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01524640 | PHASE4 | COMPLETED | Bridging Study for Killed Oral Cholera Vaccine in Ethiopia |
| NCT01579448 | PHASE4 | COMPLETED | Evaluation of a Boosting Regimen With Oral Cholera Vaccine |
| NCT01949675 | PHASE4 | COMPLETED | A Study of Two Doses of Oral Cholera Vaccine (Shanchol™) in Subjects Aged 1 Year and Older in the Philippines |
| NCT03220737 | PHASE4 | COMPLETED | VAXCHORA Pediatric Study to Assess Safety and Immunogenicity |
| NCT03373669 | PHASE4 | COMPLETED | Effect of Extended Dose Intervals on the Immune Response to Oral Cholera Vaccine |
| NCT05453253 | PHASE4 | UNKNOWN | Immune Response to a Delayed Second Dose of Oral Cholera Vaccine |
| NCT06104345 | PHASE4 | COMPLETED | Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) Vaccines |
| NCT00142272 | PHASE3 | COMPLETED | Single Dose Ciprofloxacin in the Treatment of Childhood Cholera:Randomized Controlled Clinical Trial |
| NCT00226616 | PHASE3 | COMPLETED | Zinc Supplementation in Cholera Patients |
| NCT00229944 | PHASE3 | COMPLETED | Single Dose Azithromycin in the Treatment of Adult Cholera |
| NCT00289224 | PHASE3 | COMPLETED | Randomized Controlled Trial of Killed Oral Cholera Vaccine in Kolkata |
| NCT00741052 | PHASE3 | COMPLETED | Ciprofloxacin Multiple Dose for Adult Cholera |
| NCT01895855 | PHASE3 | COMPLETED | Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera |
| NCT02027207 | PHASE3 | COMPLETED | Single Dose Oral Cholera Vaccine Study in Dhaka, Bangladesh |
| NCT02094586 | PHASE3 | COMPLETED | A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy Adults |
| NCT02100631 | PHASE3 | COMPLETED | A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults |
| NCT02434822 | PHASE3 | COMPLETED | A Study of Two Doses of Oral Cholera Vaccine (Shanchol™) in Subjects Aged 1 Year and Older in Dominican Republic |
| NCT02502331 | PHASE3 | UNKNOWN | Safety and Immunogenicity of a New Formulation of Euvichol® |
| NCT04760236 | PHASE3 | COMPLETED | Immune Non-Inferiority, Safety and Lot-to-Lot Consistency of Oral Cholera Vaccine-Simplified Compared to Shanchol™ |
| NCT05507229 | PHASE3 | UNKNOWN | A Phase III Randomized, Modified Double-blind, Multi-centric, Comparative Study, to Evaluate the Non-inferiority of Immunogenicity and Safety of Hillchol® (BBV131)to Shanchol™ Along With Lot-to-lot Consistency of Hillchol®(BBV131). |
| NCT05732766 | PHASE3 | UNKNOWN | To Evaluate Safety of Oral Cholera Vaccine Hillchol® (BBV131) |
| NCT05771779 | PHASE3 | UNKNOWN | Co-administration Study of OCV, TCV and MR |
| NCT05814042 | PHASE2/PHASE3 | COMPLETED | Next Generation ORS: Comparing ORS With Calcium vs Standard ORS in Reducing Severity of Acute Watery Diarrhea |
| NCT04326478 | PHASE2 | ACTIVE_NOT_RECRUITING | Single Dose Azithromycin to Prevent Cholera in Children |
| NCT00119197 | PHASE2 | COMPLETED | Safety and Immunogenicity of Oral Cholera Vaccine in Kolkata |
| NCT00128011 | PHASE2 | COMPLETED | Safety and Immunogenicity of a New Formulation of a Bivalent Killed, Whole-Cell Oral Cholera Vaccine |
| NCT00419133 | PHASE2 | COMPLETED | Immunogenicity of One Versus Two Doses of Killed Oral Cholera Vaccine |
| NCT00548054 | PHASE2 | UNKNOWN | Safety and Immunogenicity of a Killed Oral Cholera Vaccine in Infants |
| NCT00624975 | PHASE2 | TERMINATED | Safety and Immunogenicity of Peru-15 Vaccine When Given With Measles Vaccine in Healthy Indian and Bangladeshi Infants |
| NCT00672308 | PHASE2 | COMPLETED | Efficacy of Benefiber-Added, Reduced-Osmolarity WHO-ORS in the Treatment of Cholera in Adults |
| NCT00741637 | PHASE2 | COMPLETED | Safety and Immunogenicity of Single Dose Choleragarde® in HIV-Seropositive Adults |
| NCT01019083 | PHASE1/PHASE2 | COMPLETED | Studies of Immune Responses to Orally Administered Vaccines in Developing Country |
| NCT01233362 | PHASE2 | COMPLETED | Study of Alternative Vaccination Schedule of Oral Cholera Vaccine |
| NCT02145377 | PHASE2 | COMPLETED | PXVX0200 (CVD103-HgR) vs Shanchol in Mali |
| NCT02742558 | PHASE2 | COMPLETED | Safety and Immunogenicity of Locally Manufactured Oral Cholera Vaccine |
| NCT02823899 | PHASE1/PHASE2 | COMPLETED | Safety and Immunogenicity of Locally Manufactured New (HL-OCV) Oral Cholera Vaccine |
| NCT03251495 | PHASE2 | COMPLETED | Immunologic Responses to a Live Attenuated Oral Cholera Vaccine |
| NCT04150250 | PHASE2 | COMPLETED | Cholera Anti-Secretory Treatment Trial |
| NCT06193408 | PHASE2 | COMPLETED | Assessment of a Novel Fixed-dose Combination (FDC) Drug VR-AD-1005 for the Treatment of Acute Watery Diarrhea in Cholera |
| NCT01585181 | PHASE1 | COMPLETED | Safety and Immunogenicity of the Live Oral Cholera Vaccine Candidate PXVX0200 |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| VIBRIO CHOLERAE, LIVE ATTENUATED | 4 | 5 |
| CIPROFLOXACIN | 4 | 2 |
| ALBENDAZOLE | 4 | 1 |
| SECNIDAZOLE | 4 | 1 |
| ZINC SULFATE | 4 | 1 |
| ZINC ION | 3 | 1 |
| IOWH-032 | 2 | 2 |
| ARSENIC | 2 | 1 |
| CHEMBL1201279 | 0 | 1 |